HGF and neoplasm: Such antibody hetero-combinations can also include antibodies against a ligand, for instance vascular endothelial growth factor (VEGF) or HGF, and a receptor (Figure 1), to target both the tumor microenvironment and a tumor-specific receptor [25,26,27].